Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06089382 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study to Evaluate Sintilimab Plus Lenvatinib as Adjuvant Therapy in Hepatocellular Carcinoma With Portal Vein Tumor Thrombosis (PVTT) After Surgical Resection

StatusNot Yet Recruiting
PhasePhase 3
Started2023-11-01
View on ClinicalTrials.gov ↗
Record status
This record was last updated October 18, 2023 (before its estimated November 1, 2024 completion). Its status may not reflect the trial's current state.
Tongji Hospital
197 trials monitored
See 2 trials at risk
Liver Cancer
1,505 trials monitored
See 60 trials at risk
To compare the impact on recurrence risk of adjuvant Sintilimab (a recombinant fully human anti-PD-1 monoclonal antibody) plus Lenvatinib for patients with hepatocellular carcinoma and portal vein tumor thrombus (PVTT ) after hepatectomy.
Trial Details
NCT Number NCT06089382
Lead Sponsor Tongji Hospital
Conditions Hepatocellular Carcinoma
Enrollment 104 participants
Start Date 2023-11-01
Primary Completion 2024-11-01 (estimated)
Study Completion 2026-11-01 (estimated)
Updated on ClinicalTrials.gov 2023-10-18